Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) was the target of some unusual options trading activity on Thursday. Stock traders acquired 12,112 call options on the company. This represents an increase of 670% compared to the average daily volume of 1,574 call options.
Arcutis Biotherapeutics Stock Down 0.1 %
Shares of Arcutis Biotherapeutics stock opened at $8.49 on Friday. The company has a market cap of $982.84 million, a price-to-earnings ratio of -2.90 and a beta of 1.18. Arcutis Biotherapeutics has a twelve month low of $1.76 and a twelve month high of $13.17. The company has a quick ratio of 9.61, a current ratio of 9.89 and a debt-to-equity ratio of 0.90. The company’s 50 day moving average is $9.40 and its 200 day moving average is $9.21.
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.06. The business had revenue of $30.86 million for the quarter, compared to analysts’ expectations of $31.00 million. Arcutis Biotherapeutics had a negative net margin of 204.35% and a negative return on equity of 197.28%. During the same quarter in the previous year, the company earned ($1.16) EPS. Research analysts anticipate that Arcutis Biotherapeutics will post -1.6 EPS for the current year.
Analyst Upgrades and Downgrades
Get Our Latest Research Report on Arcutis Biotherapeutics
Insider Activity at Arcutis Biotherapeutics
In related news, insider Patrick Burnett sold 23,000 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $8.75, for a total value of $201,250.00. Following the completion of the transaction, the insider now directly owns 209,793 shares in the company, valued at approximately $1,835,688.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Patrick Burnett sold 23,000 shares of the business’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $8.75, for a total transaction of $201,250.00. Following the completion of the transaction, the insider now directly owns 209,793 shares in the company, valued at approximately $1,835,688.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Masaru Matsuda sold 5,220 shares of the business’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $9.02, for a total transaction of $47,084.40. Following the transaction, the insider now owns 183,288 shares of the company’s stock, valued at $1,653,257.76. The disclosure for this sale can be found here. In the last ninety days, insiders sold 49,995 shares of company stock worth $456,127. Corporate insiders own 9.50% of the company’s stock.
Institutional Trading of Arcutis Biotherapeutics
Several hedge funds have recently made changes to their positions in ARQT. SG Americas Securities LLC bought a new position in shares of Arcutis Biotherapeutics in the 4th quarter valued at about $79,000. Federated Hermes Inc. lifted its holdings in shares of Arcutis Biotherapeutics by 769.1% in the 4th quarter. Federated Hermes Inc. now owns 521,469 shares of the company’s stock valued at $1,684,000 after acquiring an additional 461,469 shares during the last quarter. abrdn plc bought a new position in shares of Arcutis Biotherapeutics in the 4th quarter valued at about $481,000. Jennison Associates LLC lifted its holdings in shares of Arcutis Biotherapeutics by 104.6% in the 4th quarter. Jennison Associates LLC now owns 9,066,082 shares of the company’s stock valued at $29,283,000 after acquiring an additional 4,633,907 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new position in shares of Arcutis Biotherapeutics in the 4th quarter valued at about $34,000.
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.
Featured Stories
- Five stocks we like better than Arcutis Biotherapeutics
- There Are Different Types of Stock To Invest In
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Stock Market Upgrades: What Are They?
- MarketBeat Week in Review – 8/12 – 8/16
- What is the FTSE 100 index?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.